Samsung BioLogics said Tuesday that the deal worth $31 million could grow up to $246 million by 2027 if commercial production begins. CytoDyn has applied for fast-track designation by the Food and Drug Administration (FDA).
The American company has said that a preclinical study of leronlimab showed a 98 percent reduction of breast cancer tumor metastasis after seven weeks. The target of leronlimab is a cellular receptor that appears to play multiple roles with implications in HIV infection, tumor metastases and immune signaling.
In January, Samsung Bioepis, a joint venture between Samsung BioLogics and U.S.-based pharmaceutical company Biogen, won FDA approval to sell Ontruzant, a cancer-treating biosimilar referencing Herceptin.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.